RxDoctor Payments Data

Charles Chipman, MD

Internal Medicine · Columbus, GANPI 1487655494

Payments from drug & device makers

$9,475in general payments, 2019–2025

Across 638 payments — averaging $14.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AbbVie$1K
  • Lilly USA, LLC$726
  • AstraZeneca$542
  • Novartis$511
  • Amgen$495
  • plus $5K from 47 others

What the payments were for

  • Food & beverage$9,475100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$9,475 in reported general payments places this provider in the 90th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$176,185
Medicare patients
275
Services billed
22,211

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide62$101,562
EliquisApixaban76$58,572
RybelsusSemaglutide36$54,955
JardianceEmpagliflozin45$40,476
JanuviaSitagliptin Phosphate42$36,719
TrulicityDulaglutide24$28,283
FarxigaDapagliflozin Propanediol28$24,559
MyrbetriqMirabegron25$19,448
LinzessLinaclotide28$19,026
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$17,290
Repatha SyringeEvolocumab23$17,125
EntrestoSacubitril/Valsartan12$14,756
VascepaIcosapent Ethyl25$12,254
Lantus SolostarInsulin Glargine,hum.Rec.Anlog74$10,849
XareltoRivaroxaban15$10,174

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,416$156,51798 claims
PfizerEliquis$326$58,57276 claims
Boehringer IngelheimJardiance$172$40,47645 claims
MerckJanuvia$124$36,71942 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$542$36,10955 claims
Lilly USA, LLCTrulicity$726$28,28324 claims
GSKTrelegy Ellipta, Shingrix$188$22,79741 claims
AbbVieLinzess, Synthroid$1,222$22,37471 claims
Astellas Pharma US IncMyrbetriq$364$19,44825 claims
NovartisEntresto$511$14,75612 claims
Johnson & JohnsonXarelto$126$10,17415 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Columbus

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →